MediciNova

09/03/2021

MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference (Read More)

LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

09/01/2021

MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021 (read more)

LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

08/30/2021

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
Read More Here:

LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

07/06/2021

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease
Read more here:

LA JOLLA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

06/29/2021

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. Read more here:

LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

06/28/2021

MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury. Read more here:

LA JOLLA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

06/24/2021

MEDICINOVA webinar features ALS research academicians Dr. Bjorn Oskarsson and Dr. Benjamin Rix Brooks discussing the current COMBAT-ALS trial in the US and Canada.
Check it out here:

06/07/2021

MediciNova initiates sheep study under BARDA contract.

Study will evaluate MN-166 in chlorine-induced lung injury model.

LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...